LBL-076

N/A

Report date: 2026/03/19 17:03:36

First In Class

Base Information

Drug NameLBL-076

Drug Alias NameLBL-076LBL076

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-CD38Anti-GPRC5DAnti-CD3

TargetsLymphocyte differentiation antigen CD38G-protein coupled receptor family C group 5member DT cell surface glycoprotein CD3

Therapy Area/IndicationsMultiple Myeloma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesNanjing Leadsbiolabs Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesNanjing Leadsbiolabs Co Ltd

Inactive CompaniesN/A

Active IndicationsMultiple Myeloma

Inactive IndicationsN/A

Other Information

ATC CodeN/A